Technologies

• OmicScouts enables access to innovative, system-wide methods to monitor protein activity and function
• Our suite of more than 15 proteomic technologies and assays allows the dissection of disease phenotypes and their modulation by bioactive molecules at unprecedented resolution and dimensionality
• We have since established an excellent track record in delivering important results to pharmaceutical and biotechnology companies, as well as academic partners
• Each technology can be scaled up for screening and high throughput profiling campaigns
• Our LC-MS/MS platform allows for automated and scalable proteomics experiments to process cell biology, biochemical, chemical biology and (pre-) clinical samples
• Discovery and targeted proteomics supporting all common quantification and data acquisition technologies
• Our portfolio of technologies can be a crucial factor for drug discovery of protein degraders, molecular glues, covalent compounds, or RNA-targeting modalities (i.e., for novel chemical modalities)

Recommended reading

Meissner, F., Geddes-McAlister J., Mann M., Bantscheff, M. (2022). The emerging role of mass spectrometry-based proteomics in drug discovery, Nat Rev Drug Discov 21(9):637-654. [Link]

Aebersold, R., and Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function, Nature 537(7620):347-55. [Link]

Schirle, M., Bantscheff, M., and Kuster, B. (2012). Mass Spectrometry-based Proteomics in Preclinical Drug Discovery, Chem Biol 19(1):72-84. [Link]